European Archives - Page 433 of 1017 - European Medical Journal

The hard sell of cell and gene therapies

While the potential of cell and gene therapies (CGTs) is huge, the high cost raises concerns from payers. We explore how the industry can drive the adoption of CGTs to ensure that they reach patients around the world, rather than just those in private markets

Seeking solutions to low income low access

During the pandemic, low-to-middle-income countries (LMICs) have often been reliant on vaccine handouts from global initiatives and affluent nations. What are the emerging solutions that could improve access to vaccines in LMICs and self-sufficiency?

What is possible with preventative technology?

Tech giants have seized a huge share of the health and preventive technology market, but how could partnerships between the pharmaceutical and tech industries benefit patients and healthcare systems?

Interview: Neel Basudev

To be honest, my initial foray into the field of diabetes was by chance, as I took on the management of diabetes at the practice when I joined as a salaried general practitioner.

EMJ Oncology 9.1 2021 Feature Image

EMJ Oncology 9.1 2021

Welcome to the latest issue of EMJ Oncology! This e-journal brings you the latest news and novel findings from this year’s European Society…

EMJ Oncology 9.1 2021 Feature Image

Review of the European Society for Medical Oncology (ESMO) Congress 2021: An Enhanced Virtual Experience

AN INTERNATIONAL COLLECTIVE of oncology clinicians and researchers came together to share the most recent updates in patient care and…

A Phase II Prospective Trial of Frontline Cabozantinib in Metastatic Collecting Ducts Renal Cell Carcinoma: the BONSAI Trial (Meeturo 2)

Metastatic collecting ducts carcinoma is biologically poorly characterised and under-represented in prospective randomised trials.

Navigating the Current Treatment Landscape in Oesophageal Cancer with an Eye Toward the Future

The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…

ESMO: Reshaping the Future of Clinical Trials in Oncology

Opening the session, Calvo presented a compelling and balanced case about the potential that Phase 0 (Ph0) trials hold for increasing…

Editor’s Pick: More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.